AnaptysBio, Inc. ANAB
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 107.73% | 157.01% | 196.42% | 304.17% | 387.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 107.73% | 157.01% | 196.42% | 304.17% | 387.20% |
| Cost of Revenue | -23.33% | -17.01% | -1.15% | 14.20% | 25.01% |
| Gross Profit | 284.66% | 235.93% | 116.87% | 64.02% | 49.64% |
| SG&A Expenses | 42.16% | 19.69% | 6.29% | 8.11% | 1.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.70% | -9.47% | 0.45% | 12.82% | 19.30% |
| Operating Income | 140.68% | 141.67% | 79.53% | 44.45% | 35.25% |
| Income Before Tax | 81.06% | 91.00% | 48.96% | 22.10% | 13.92% |
| Income Tax Expenses | 240.43% | 5,366.67% | 1,440.00% | 1,440.00% | 1,275.00% |
| Earnings from Continuing Operations | 80.95% | 90.89% | 48.91% | 22.06% | 13.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.95% | 90.89% | 48.91% | 22.06% | 13.89% |
| EBIT | 140.68% | 141.67% | 79.53% | 44.45% | 35.25% |
| EBITDA | 141.47% | 142.38% | 79.85% | 44.59% | 35.35% |
| EPS Basic | 82.33% | 94.31% | 53.92% | 29.37% | 21.00% |
| Normalized Basic EPS | 79.39% | 93.53% | 64.12% | 38.00% | 29.54% |
| EPS Diluted | 77.69% | 89.97% | 53.49% | 29.25% | 20.88% |
| Normalized Diluted EPS | 73.94% | 88.51% | 63.74% | 38.00% | 29.54% |
| Average Basic Shares Outstanding | -27.28% | -23.09% | 7.39% | 10.72% | 10.12% |
| Average Diluted Shares Outstanding | -1.54% | 3.52% | 8.47% | 10.72% | 10.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |